Beating cancer,
one test at a time

 

Oncimmune profiles the body’s immune response to detect evidence of the body’s natural response to cancer, which can be detected far earlier than cancerous cells themselves, or the cancer’s DNA.

 

Our proprietary platform

Our proprietary platform — underpinned by rapid biomarker discovery and our comprehensive immunogenic protein library of over 8,000 antigenic proteins — has a role in supporting case-selection, complementing diagnostic evidence, and facilitating therapeutic decision-making; and is a keystone to the future of cancer care.

 

Our patented technology measures blood levels of autoantibodies to tumour-associated antigens, the combination of which is highly specific for target cancers, whose characteristic signal can be detected four years or more before standard clinical diagnosis.

 

Earlier Detection

Enabling the earliest detection of cancer is key to timely initiation of treatment, potentially saving lives and significantly reducing healthcare costs.

 
 
full width image

Complementary Diagnostics

Oncimmune is developing complementary diagnostics to monitor the therapeutic outcome of patients placed on pioneering cancer treatments as well as identifying potential adverse effects.

Partnering

Our tests are complementary to in vitro and in vivo diagnostic technologies, making them valuable additions to both established and new care pathways, potentially generating more information and greater confidence in determining appropriate treatment selection.

We partner with leading developers and distributors to make our technology available globally.

 

Oncimmune is working to change how cancer is diagnosed and treated. Whilst early detection is already improving cancer survival, immuno-profiling is the frontier to improving outcomes.

 

  • Oncimmune was founded in 2002 and launched its platform technology in 2009, followed by its first commercial tests, EarlyCDT—Lung and EarlyCDT—Liver.
  • To date, over 155,000 tests have been performed for patients worldwide and EarlyCDT—Lung is being used in the largest-ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) ECLS study of 12,210 high-risk smokers in Scotland.
  • Oncimmune is headquartered in Nottingham (UK) with offices in London (UK), Dortmund (Germany) and Shanghai (China).
  • Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L.
  • Oncimmune acquired the immuno-profiling company Protagen AG in March 2019.

Leading Early Cancer Biomarker Technology